Journal of Neurology and Neuroscience

Keywords

Alzheimer disease; Stress; Immune system; Non-pharmacological therapies; Well-being

Introduction

In the last few years, along with a longer life expectancy, new disorders have appeared. Among these diseases, Alzheimer´s disease (AD) is the most common dementia in elderly population mostly affecting individuals beyond the age of 65 (60% to 70% of the total) and its prevalence increases dramatically with age [1].

From a neurobiological point of view, it is known that this disease is characterized by a chronic and progressive neurodegenerative process resulting from the intracellular and extracellular abnormal accumulation of proteins. The main representatives of these proteins are beta-amyloid and hyperphosphorylated. Overaccumulation of these aggregates leads to synaptic dysfunction and subsequent neuronal loss [2]. On the other hand, different neuroanatomic structures are heavily affected, such as the hippocampus or frontal cortex with serious cognitive, emotional and behavioral consequences. In fact, anxiety, depression or poor wellbeing have been described in these people [3].

The etiology of the disease typically has various causes, for example genetic causes, but in the last few years many authors have shown that other biological and environmental factors can be involved. There are studies which have demonstrated that the immune system (IS) and endocrine disorders, due to external factors such as stress [4,5], can influence the apparition of this disorder.

Unfortunately, this severe, irreversible, chronic and progressive neurodegenerative disease eventually leads to death in many cases and, nowadays, it has no cure. For this reason, it is essential to make progress with the objective to find new targets in the treatment and to study all the behavioral, cognitive and emotional parameters involved. Moreover, the absence of drug treatments and the high prevalence of AD, along with the burden of the disease on patients, their families and society, have led to the evaluation of new alternative therapies in an attempt to improve patient wellbeing [6]. In this line, non-pharmacological therapies (such as physical exercise or music therapy) have been showing positive results.

This review is aimed at providing an update of the studies on the role of stress, immune system, well-being and nonpharmacological therapies in AD. First, we will describe the role of stress in this disorder. Secondly, we will explain the influence of the immune system by explaining the most important studies in this area. In the third place, we will discuss the result of the studies that determine the role of other associated variables, such as anxiety, depression or wellbeing perceived. Finally, we will present the main alternative therapies to improve symptoms in AD. The main objective of this theoretical study is to propose new priorities for future work in the field.

Stress and AD

Different studies show the role of stress in the appearance and maintenance of several disorders with neurobiological consequences, such as drug addiction [7] or AD [8], and other emotional and cognitive consequences, like poor memory or depressive symptoms.

The physiological stress response is modulated through the hypothalamic-pituitary-adrenal (HPA) axis [9] that stimulates the hypothalamus, which initiates the production of corticotrophin-releasing hormone (CRH). This activates the pituitary gland, which secretes adrenocorticotropic hormone (ACTH). The ACTH stimulates the adrenal gland cortex where the main stress regulating hormone, cortisol, is located. Cortisol is considered to be the most reliable biomarker for measuring physiological stress levels in any biological sample.

When cortisol is persistently high, the cognitive function is compromised based on changes that occur in various parts of the brain and in levels of certain neurotransmitters. In addition, it induces the suppression of neurogenesis in the hippocampus inducing memory loss. Moreover, relevant authors in AD research have demonstrated that the relationship between cortisol levels and memory performance in the aging process could vary according to the presence or absence of cognitive impairment [10]. Also, a recent study in our laboratory [4] has shown that de level of cortisol in people with and without AD is different.

This substance accumulates in blood, saliva, sweat, hair, and urine. Among these, salivary cortisol is used as the most common biomarker of psychological stress because it is a noninvasive procedure and does not generate anxiety for the patient [11].

Immune System and AD

As we have previously mentioned, the etiology typically has various causes. Between one of them, several disorders of the immune system (IS) are included among the non-genetic risk factors for AD too.

The Immune System (IS) is altered in patients with AD mainly due to the inflammatory component of the disease, being Immunoglobulin A (IgA) one of the components of the IS which is severely altered when there is inflammation.

Moreover, data show that stress system and immune system are related. Chronic stress has been associated with detrimental or maladaptive neuroendocrine and immunological changes [5] and there seems to be a relationship between IS and stress, which may influence the appearance of AD. Furthermore, it has already been shown that the level of IgA in saliva is adequate to measure the immune response to a psychological intervention and to determine a situation of emotional stress [4]. Microglia and astrocytes are activated and secrete inflammatory cytokines and chemokines via a disturbed blood-brain barrier; peripheral immune cells are activated and recruited towards inflamed brain lesions and amyloid plaques. These cells are not able to control inflammation and the associated detrimental immune responses [12]. The values of immunoglobulin A (IgA) vary rapidly as a result of the immunological alterations, so this immunoglobulin is a good indicator of the immunological system’s activity at all times. Quantifying the level of IgA in saliva enables changes in immunocompetence to be determined, which may be one-off or produced by some kind of therapeutic intervention [16]. Also, in the laboratory of Prof. De La Rubia it has been demonstrated that the level of IgA in patients, with and without AD, is different and it supports the idea that patients with AD suffer from an immune alteration, which could partly explain the pathogenesis of the disease which presents with great inflammation [4]. The difference in IS in patients with and without AD is based in a hyperactivity of this system in AD patients. In our study we observed that the levels of IgA in AD patients were 103.97 ± 65.62 versus 23.79 ± 16.1 in patients without AD. Moreover, it was seen that there is a tendency in the group of participants without AD since, when cortisol increases, there is a decrease in IgA in saliva, while in AD participants, when cortisol increases, the IgA level in saliva increases too. All of these changes can be explained due to cellular, molecular and physiological changes in the organism that are also related to the mood of patients [13-15].

Psychological and Emotional State in AD: Well-being Perceived

The most relevant symptoms in AD are cognitive and behavioral disorders, but mood impairments have also been described. In fact, the appearance and development of the disease are associated with anxiety or depression [17]. Moreover, the appearance of these emotional symptoms is associated with the response of cortisol and IS too. There is a close relationship between the systems.

Regarding anxiety, it has been demonstrated, by using animal models, that elevated cortisol in AD subjects prompted the hypothesis that stress and glucocorticoids are involved in the development and/or maintenance of AD, and that an intracerebroventricular injection of amyloid-β peptide in rats induces memory impairment with alteration of anxiety responses [18].

On the other hand, other studies show evidence that high level of chronic stress causes depression basically because of monoaminergic changes that are generated in various brain regions and the suppression of hippocampal neurogenesis [19]. This neuronal degeneration could also affect the limbic structures associated with emotional regulation, which explains the appearance of anxiety in many patients.

Moreover, it seems that poor well-being may affect the immune response, too. The proficiency of the Immune system is related to the emotional wellbeing. Wellbeing is defined as a combination of positive emotions, engagement, meaningful relationships and a sense of accomplishment [20], reflecting the positive aspects of mental health. Persistent psychological stress has been related to the disruption of and it triggers the onset of neuropsychiatric conditions. It has been shown that psychological stress adversely affects the normal functioning of the contributing to the pathophysiology of some neuropsychiatric disorders. Therefore, it seems that psychological stress due to a lack of wellbeing, and severe mental disorders, affect the immune response and the apparition of diseases mediated by the Immune system.

AD patients have well-being impairment and emotional problems such as depression or anxiety. It has been known for some time that cheerfulness and positive emotions are accompanied by an increase in salivary IgA levels. However, immune system is not the only biological system involved with wellbeing in AD. In the last few years, other biological systems seem to have an influence in mood state, for example, the adrenergic system. It is known that noradrenalin is the sympathetic nervous system’s main neurotransmitter and provides information about the patient’s emotional symptoms, too. An increase in endogenous noradrenalin is recorded when subjects receive emotional stimuli, and are significantly correlated to the suppression of these stimuli but not to the suppression of emotionally neutral stimuli. Activation of the adrenergic system can be evaluated by quantifying alphaamylase in parotid gland saliva [21], thus becoming another important biomarker of the emotional state too.

The increase in noradrenalin is related not only to emotions but also to increased memory performance in patients with AD. Consequently, elevations in alpha-amylase may be indirectly associated to improved cognitive function – which is precisely the main function found to be impaired in patients with AD.

Non-Pharmacological Therapies in AD

We know that, at present, AD has no cure and pharmacological treatment only alleviates the symptoms. For this reason, the role of non-pharmacological therapies (NFTs) is important, which are very diverse and are based on brain plasticity. These types of treatments are defined as interventions that aim to improve ill or healthy people’s quality of life based on the use of non-chemical agents. In patients with mild AD, it has been demonstrated that such therapies improve neuroplasticity, produce improved psychological and physical well-being, optimize the quality of life and encourage social integration [22].

For example, it has been shown that aerobic exercise reduces the risk of dementia, AD and cognitive impairment [23], besides reducing the risk of suffering from psychological and emotional disorders such as anxiety and depression. New technologies are becoming more popular in the field of physical exercise due to the information and communication technologies (ICTs), based on the use of software on computers, game consoles, tablets, smart phones and so on, with the aim of training or stimulating cognition and memory. In this line, studies in our laboratory have demonstrated that exercise based on ICTs reduces anxiety, depression and cortisol levels in AD patients. [24].

However, there is a multitude of therapies which produce improved psychological and physical wellbeing in AD patients. Within these therapies, music has been shown to have benefits on the patients’ quality of life, preserving the skills of expression and socialization, improving anxiety, depression, irritability and social isolation [25]. Therefore, this therapy is being used in the field of dementia as a possible alternative for alleviating various conditions. It induces brain plasticity in the early stages of the disorder, suggesting that it may be a good alternative. Concerning stress levels, music therapy, widely used for stress release in all areas of medicine, tends to be a reliable and efficacious treatment for critically ill patients. It can lessen stress response, decrease anxiety during mechanical ventilation and induce an overall relaxation response without the use of medication. For all this, music therapy has been shown to have benefits in the patients’ quality of life, preserving the skills of expression and socialization while improving (i.e., decreasing) anxiety, depression, irritability and social isolation and becoming a new target to treatment in AD [25,26].

Conclusions

Over the last years, the increase of advanced age people in our society has created the need to research on new ways of therapy and on new disorders. AD is the most important disorder in western societies associated with the longevity of individuals and nowadays it has no cure. For this reason, it is important to generate new developments and make progress in this area in order to maintain quality of life.

Regarding that, it seems that stress and IS can be new targets to understand this disorder and to ascertain factors involved in the progression of symptoms. It has been shown that stress can affect several neurobiological disorders, among which AD is found, which helps us to work towards determining new diagnostic and treatment tools. Moreover, the IS changes in individuals suffering from AD, being stress levels and IgA different in patients with and without AD. Furthermore, it seems that both systems are connected, this being an important aim for our future work.

On the other hand, it is known that patients with AD have changes in their emotions and this can induce pathologies, such as anxiety and depression, or poor wellbeing that can influence the development of the disorder. Moreover, the main contribution of this manuscript is that all the systems described are involved at the same time (stress system, immune system and emotional system) and, as a consequence, the therapeutic interventions must be multifactorial. For this reason, new non-pharmacological therapies, unknown until now in the treatment of this disorder, can be a good option to treat AD.

All in all, the study of the role of stress, emotions and IS can increase the knowledge about the variables involved in AD in order to contribute to future therapies and create new pharmacological and psychological goals in the treatment of AD.

18524

References

1. Bullain SS, Corrada MM (2013) Dementia in the oldest old. Continuum: Lifelong Learning in Neurology 19: 457-469.
2. Bachurin SO, Bovina EV, Ustyugov AA (2017) Drugs in clinical trials for Alzheimer Disease: The major trends. Med Res Rev.
3. SuárezGA, Crutch SJ, Franco ME, Gil-Néciga E (2015) Neuropsychiatric symptoms in Posterior cortical atrophy and Alzheimer disease. J Geriatr Psychiatry Neurol 29: 65-71.
4. De laRubia-Ortí JE, Castillo S, Benlloch M, Rochina M, Corchón AS, et al.(2017) Impact of the relationship of stress and the immune system in the appearance of Alzheimer’sdisease. J. Alzheimers Dis 55:899-903.
5. Jeckel M, Lopes RP, Berleze MC, Luz C, Feix L, et al. (2009) Neuroendocrine and immunological correlates of chronic stress in ‘strictly healthy’populations. Neuroimmunomodulation 17: 9-18.
6. Olazaran J, Reisberg B Clare L, Cruz I, Pena-Casanova J(2010) Nonpharmacological therapies in Alzheimer Disease: a systematic review of efficacy. Dement GeriatrCognDisord 30: 161-178.
7. García-Pardo MP, Blanco-Gandía MC, Valiente-Lluch M, Rodríguez-Arias M, Miñarro J, et al. (2015) Long-term effects of repeated social stress on the conditioned place preference induced by MDMA in mice. ProgNeuropsychopharmacolBiol Psychiatry 63: 98-109.
8. Lanté F, Chafai M, Raymond EF, Pereira ARS, Mouska X, et al. (2015) Subchronic glucocorticoid receptor inhibition rescues early episodic memory and synaptic plasticity deficits in a mouse model of Alzheimer Disease. Neuropsychopharmacology40: 1772-1781.
9. Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, et al. (2015) Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. Neurobiol. Aging 36: 601-607.
10. Souza-Talarico JN, Chaves EC, Lupien SJ, Nitrini R, Caramelli P (2010) Relationship between cortisol levels and memory performance may be modulated by the presence or absence of cognitive impairment: evidence from healthy elderly, mild cognitive impairment and Alzheimer Disease subjects. J. Alzheimers Dis 19: 839-848.
11. Iliadis SI, Comasco E, Sylvén S, Hellgren, C, Poromaa IS, et al. (2015) Prenatal and postpartum evening salivary cortisol levels in association with peripartum depressive symptoms. PloS one 10: e0135471.
12. Goldeck D, Witkowski J, Fulop T, Pawelec G (2016) Peripheral immune signatures in Alzheimer disease. Curr Alzheimer Res 13: 739-749.
13. Ciaramella A, Salani F, Bizzoni F, Orfei MD, Caltagirone C, et al. (2016) Myeloid dendritic cells are decreased in peripheral blood of Alzheimer´s disease patients in association with disese progression and severity of depressive symptoms. J neuroinflammation 13: 18.
14. Delbarba A, Abate G, Prandelli C, Marziano M, Buizza L, et al. (2016) Mitochondrial alterations in peripheral mononuclear blood Cells from Alzheimer´s disease and mild cognitive impairment patients. Oxid Med Cell Longev.
15. Venegas C, Heneka MT (2017) Danger-associated molecular patterns in Alzheimer´s disease. J LeukocBiol 101: 87-98.
16. Abdou AM, Higashiguchi S, Horie K, Kim M, Hatta H, et al. (2006) Relaxation and immunity enhancement effects of γ-aminobutyric acid (GABA) administration in humans. Biofactors 26: 201-208.
17. Aznar S, Knudsen GM (2011) Depression and Alzheimer’sdisease: Is stress the initiating factor in a common neuropathological cascade?. JAlzheimers Dis 23: 177-193.
18. Zussy C, Brureau A, Keller E, Marchal S, Blayo C, et al. (2013) Alzheimer disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid-β peptide injection in rats. PloS one 8: e53117.
19. Mahar I, Bambico FR, Mechawar N, Nobrega JN (2014) Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. NeurosciBiobehav Rev 38: 173-192.
20. Huppert FA, So TC (2013) Flourishing across Europe: Applications of a new conceptual framework for defining well-being. Soc Indic Res 110: 837-861.
21. Segal SK, Cotman CW, Cahill LF (2012) Exercise-induced noradrenergic activation enhances memory consolidation in both normal aging and patients with amnestic mild cognitive impairment. J. Alzheimers Dis 32: 1011-1018.
22. Viola LF, Nunes PV, Yassuda MS, Aprahamian I, Santos FS, et al. (2011) Effects of a multidisciplinar cognitive rehabilitation program for patients with mild Alzheimer Disease. Clinics 66: 1395-1400.
23. Strohle A, Schmidt DK, Schultz F, Fricke N, Staden T, et al. (2015) Drug and exercise treatment of Alzheimer disease and mild cognitive impairment: A systematic review and meta-analysis of effects on cognition in randomized controlled trials. Am. J. Geriatric Psychiatry 23: 1234-1249.
24. De la Rubia JE, Cabanes C, Sancho S, PlateroArmero JL, Benlloch M, et al. (2016) Impact on information and communication technologies versus anaerobic physical activity in patients with mild Alzheimer´s disease: A pilot study. J. Neuropsychiatry 6: 456–460.
25. Mofredj A, Alaya S, Tassaioust K (2016) Music therapy, A review of the potential therapeutic benefits for the critically ill. J Crit Care 35:195-199.
26. Gomez GM, Gomez GJ (2016) Music therapy and Alzheimer Disease: Cognitive, psychological, and behavioural effects. Rev Neurol.